Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
Primary Purpose
Myeloid Leukemia, Precursor Myeloid Neoplasms, Lymphoid Neoplasms
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Sponsored by

About this trial
This is an interventional treatment trial for Myeloid Leukemia
Eligibility Criteria
Inclusion Criteria:
- Patients planned to undergo an allogeneic HSCT with myeloablative conditioning
- Age 18 - 65 years
- Myeloid leukemia respectively related precursor neoplasms (acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome), or lymphoid neoplasms (acute lymphoblastic leukemia/lymphoma, mature B-/T-/natural killer (NK)-cell neoplasms).
- Human Leukocyte Antigen (HLA)-identical sibling donor or matched unrelated (min. 10/10 Ag matched)
- Patients with a history of hepatitis might be included, if no contraindication for HSCT exists.
- Patient must give written informed consent
Exclusion Criteria:
- Indication other than myeloid leukemia respectively related precursor neoplasms, or lymphoid neoplasms.
- Severe liver damage for > 2 weeks (bilirubin > 3xupper limit normal (ULN) or ASAT/ALAT > 5xULN)
- HIV infection
- Donor other than HLA-identical sibling or min. 10/10 matched unrelated donor
- Pregnant or lactating women
- Lack of written informed consent
Sites / Locations
- University Hospital, Basel
- University Hospital Geneva
- University Hospital Zurich
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
BU-CY
CY-BU
Arm Description
Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
Outcomes
Primary Outcome Measures
Liver toxicity
Liver toxicity, assessed as absolute serum values of ASAT, ALAT, GGT, Alkaline Phosphatase, bilirubin at day 30.
Secondary Outcome Measures
VOD
Incidence and severity of "veno occlusive disease (VOD)" at day 30
Acute graft-versus-host disease (GvHD)
Incidence and severity of acute GVHD, by organ (skin, liver, gut) at day 30 and day 100
Toxicity
Organ toxicity at day 30 and day 100
Efficacy
Survival, relapse and non-relapse mortality at day 30 and day 100
Cumulative liver values
Cumulative serum values of aspartate transaminase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyltransferase (GGT), Alkaline Phosphatase, bilirubin for days 0, 10, 20 and 30
Maximum liver values
Maximum serum values of ASAT, ALAT, GGT, alkaline phosphatase (AP), bilirubin at any time between day 0 and day 30
Full Information
NCT ID
NCT01779882
First Posted
January 28, 2013
Last Updated
March 1, 2018
Sponsor
University Hospital, Basel, Switzerland
Collaborators
University Hospital, Zürich, University Hospital, Geneva
1. Study Identification
Unique Protocol Identification Number
NCT01779882
Brief Title
Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
Official Title
Cyclophosphamide-Busulfan Versus Busulfan-Cyclophosphamide as Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: a Prospective Randomized Study to Assess Liver Toxicity
Study Type
Interventional
2. Study Status
Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
January 6, 2018 (Actual)
Study Completion Date
January 6, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
University Hospital, Zürich, University Hospital, Geneva
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myeloid Leukemia, Precursor Myeloid Neoplasms, Lymphoid Neoplasms
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
72 (Actual)
8. Arms, Groups, and Interventions
Arm Title
BU-CY
Arm Type
Active Comparator
Arm Description
Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
Arm Title
CY-BU
Arm Type
Experimental
Arm Description
Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
Intervention Type
Drug
Intervention Name(s)
Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Intervention Description
Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Intervention Description
Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Primary Outcome Measure Information:
Title
Liver toxicity
Description
Liver toxicity, assessed as absolute serum values of ASAT, ALAT, GGT, Alkaline Phosphatase, bilirubin at day 30.
Time Frame
Day 30
Secondary Outcome Measure Information:
Title
VOD
Description
Incidence and severity of "veno occlusive disease (VOD)" at day 30
Time Frame
Day 30
Title
Acute graft-versus-host disease (GvHD)
Description
Incidence and severity of acute GVHD, by organ (skin, liver, gut) at day 30 and day 100
Time Frame
Day 30 and Day 100
Title
Toxicity
Description
Organ toxicity at day 30 and day 100
Time Frame
Day 30 and Day 100
Title
Efficacy
Description
Survival, relapse and non-relapse mortality at day 30 and day 100
Time Frame
Day 30 and Day 100
Title
Cumulative liver values
Description
Cumulative serum values of aspartate transaminase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyltransferase (GGT), Alkaline Phosphatase, bilirubin for days 0, 10, 20 and 30
Time Frame
Day 0, 10, 20 and 30
Title
Maximum liver values
Description
Maximum serum values of ASAT, ALAT, GGT, alkaline phosphatase (AP), bilirubin at any time between day 0 and day 30
Time Frame
Day 0, 10, 20 and 30
Other Pre-specified Outcome Measures:
Title
Cytokines measurement
Description
To test the correlation between order of application of the conditioning regimen and the levels of proinflammatory cytokines as well as the correlation between levels of cytokines and development of acute GVHD, plasma samples will be collected at different time points.
Time Frame
Day -8, 0, 10, 20 and 30
Title
Pharmacogenomics
Description
The current hypothesis is that some functional polymorphisms of genes, which control important enzymes in BU and CY metabolism, contribute to the observed interindividual variability in toxicity after allogeneic HSCT.
Time Frame
Day -8, -3 and 0
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients planned to undergo an allogeneic HSCT with myeloablative conditioning
Age 18 - 65 years
Myeloid leukemia respectively related precursor neoplasms (acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome), or lymphoid neoplasms (acute lymphoblastic leukemia/lymphoma, mature B-/T-/natural killer (NK)-cell neoplasms).
Human Leukocyte Antigen (HLA)-identical sibling donor or matched unrelated (min. 10/10 Ag matched)
Patients with a history of hepatitis might be included, if no contraindication for HSCT exists.
Patient must give written informed consent
Exclusion Criteria:
Indication other than myeloid leukemia respectively related precursor neoplasms, or lymphoid neoplasms.
Severe liver damage for > 2 weeks (bilirubin > 3xupper limit normal (ULN) or ASAT/ALAT > 5xULN)
HIV infection
Donor other than HLA-identical sibling or min. 10/10 matched unrelated donor
Pregnant or lactating women
Lack of written informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nathan Cantoni, MD
Organizational Affiliation
Kantonsspital Aarau, Switzerland
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sabine Gerull, MD
Organizational Affiliation
University Hospital, Basel, Switzerland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gayathri Nair, MD
Organizational Affiliation
University Hospital, Zürich
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yves Chalandon, MD
Organizational Affiliation
University Hospital Geneva, Switzerland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jakob Passweg, MD
Organizational Affiliation
University Hospital, Basel, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital, Basel
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
University Hospital Geneva
City
Geneva
ZIP/Postal Code
1205
Country
Switzerland
Facility Name
University Hospital Zurich
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland
12. IPD Sharing Statement
Citations:
PubMed Identifier
20548339
Citation
Cantoni N, Gerull S, Heim D, Halter J, Bucher C, Buser A, Tsakiris DA, Passweg J, Tichelli A, Stern M, Gratwohl A. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011 Mar;46(3):344-9. doi: 10.1038/bmt.2010.137. Epub 2010 Jun 14.
Results Reference
background
Learn more about this trial
Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
We'll reach out to this number within 24 hrs